Business Context and Reporting Period
Capstone Therapeutics Corp. filed this unaudited Form 10-Q for the quarter ended June 30, 2014. The filing identifies the company as a development-stage biotechnology company; the request metadata refers to Capstone Holding Corp., but that name does not appear in the filing.
The company operates primarily through a virtual model focused on developing peptide candidates. Its 60%-owned LipimetiX Development LLC joint venture is advancing AEM-28 for severe refractory hypercholesterolemia and homozygous familial hypercholesterolemia. AZX100 dermal-scar development was discontinued in 2012, although limited fibrosis studies and partnering efforts continue.
Financial Highlights
| Metric | Three Months Ended June 30, 2014 | Six Months Ended June 30, 2014 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| General and administrative expense | $222,000 | $674,000 |
| Research and development expense | $1.172 million | $1.802 million |
| Net loss attributable to Capstone stockholders | $1.391 million, or $0.03 per share | $2.413 million, or $0.06 per share |
| Cash flow used in operating activities | Not separately reported | $2.065 million |
| Cash and cash equivalents at period-end | $4.193 million, including $826,000 reserved for the joint venture | |
| Total assets | $5.283 million | |
| Current liabilities | $430,000 |
No debt or interest-bearing borrowings are reported in the condensed financial statements. The filing does not provide a meaningful operating margin because the company reported no revenue and incurred continuing research and administrative expenses.
Material Changes Versus Prior Comparable Period
- Second-quarter net loss increased to $1.391 million from $1.008 million, while six-month net loss attributable to stockholders increased to $2.413 million from $2.004 million.
- Second-quarter research and development expense increased to $1.172 million from $749,000, primarily due to higher LipimetiX joint venture expenses.
- Six-month research and development expense increased to $1.802 million from $1.661 million, while general and administrative expense declined to $674,000 from $711,000.
- Cash used in operations was $2.065 million for the first six months, compared with $2.086 million in the prior-year period. Cash declined from $6.258 million at December 31, 2013 to $4.193 million at June 30, 2014.
- All joint venture losses were allocated to Capstone after March 31, 2013 because common ownership equity had been reduced to zero, contributing to the current-period loss attributable to Capstone stockholders.
- AEM-28 Phase 1a and Phase 1b/2a trials commenced in Australia in April and June 2014, respectively. The initial development plan was expected to continue through the fourth quarter of 2014.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management estimated 2014 expenditures of approximately $4.0 million, including approximately $2.5 million for LipimetiX, excluding potentially significant qui tam litigation costs.
- Management stated that cash and short-term investments at June 30, 2014 were expected to fund presently projected requirements for the next twelve months, but additional capital would be required to complete clinical development and pursue regulatory approvals.
- The company may need financing, partnering, licensing, asset sales, or other transactions. Such funding may be unavailable or may materially dilute existing stockholders.
- A qui tam lawsuit relating to the former bone-device business remains pending. The government declined to intervene, no trial date had been set, and the potential damages could exceed the company’s available resources. Management did not record a material loss contingency but acknowledged that an adverse outcome could materially impair liquidity and threaten continued operations.
- LipimetiX Australia had incurred AUD$634,000 of potentially eligible research and development expenditures. No Australian refundable tax credit was recorded because eligibility and the amount of qualified expenditures remained uncertain.
- The company adopted or planned early adoption of ASU 2014-10 eliminating development-stage entity reporting requirements; management expected no impact on the financial statements.
- A June 24, 2014 Tax Benefit Preservation Plan authorized rights associated with 1,000,000 shares of Series A preferred stock. The plan may delay or prevent a change in control and could have dilutive effects.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting. The filing stated that there were no material changes to previously disclosed risk factors.
Important Facts for Investors to Verify
- Confirm the legal issuer name and ticker because the filing is for Capstone Therapeutics Corp., not Capstone Holding Corp.
- Assess whether the $4.193 million cash balance, including $826,000 restricted to the joint venture, is sufficient relative to projected spending and litigation exposure.
- Track AEM-28 trial enrollment, safety and efficacy results, regulatory progress, and the joint venture’s remaining cash.
- Review the potential financial impact and status of the qui tam litigation, including whether a trial date or settlement has been established.
- Determine the company’s ability to obtain additional capital without substantial dilution and whether AZX100 can attract a development or licensing partner.
- Review outstanding options and warrants: 3,327,835 shares were subject to options and warrants at exercise prices ranging from $0.16 to $6.25 per share as of June 30, 2014.